October 21, 2019
In another setback for Daiichi Sankyo, a key European panel has given a thumbs-down for approval of the company’s acute myeloid leukemia (AML) treatment quizartinib, some four months after the US FDA rejected the drug despite clearance by Japanese regulators...read more